Investment Rating - The report maintains a "Buy" investment rating for the company [1] Core Views - The company experienced stable operational performance, with a focus on expanding new retail customer base [1] - The gross margin is under marginal pressure, but the sales expense ratio is expected to smooth out gradually [1][2] - The company aims to enhance product value and has potential for significant growth in the baking category [2] - Continuous development of new retail customers and diversification of distributor channels are key strategies [3][6] - Short-term pressures from customer terminals and product iterations are expected, but the company is well-positioned to explore new growth points [7] Financial Performance Summary - In 2024, total revenue was 1.868 billion yuan, a decrease of 2% year-on-year, with a net profit of 84 million yuan, down 38% [1] - For Q1 2025, total revenue was 470 million yuan, an increase of 1% year-on-year, with a net profit of 21 million yuan, down 38% [1] - The company projects revenue growth rates of 5.4%, 8.7%, and 9.8% for 2025, 2026, and 2027 respectively [9] - The diluted earnings per share (EPS) are forecasted to be 0.91 yuan in 2025, 1.02 yuan in 2026, and 1.16 yuan in 2027 [9] Revenue Breakdown - In 2024, revenue from staple foods and snacks was 914 million yuan and 439 million yuan, respectively, both showing declines [2] - The baking category maintained stable revenue at 365 million yuan in 2024, with expectations for high double-digit growth in 2025 [2] - Revenue from frozen prepared dishes and others surged by 273% to 142 million yuan in 2024, driven by multi-channel efforts [2] Channel Performance - Direct sales channel revenue increased by 4% to 809 million yuan in 2024, with ongoing efforts to expand into new retail channels [3] - Distributor channel revenue decreased by 6% to 1.051 billion yuan in 2024, but is expected to stabilize with improved efficiency [6]

Investment Rating - The report maintains a "Buy" investment rating for the company [10] Core Views - The company is expected to achieve significant growth in its veterinary pharmaceutical business in 2025, driven by both volume and price increases [5][6] - The company reported a revenue of 2.371 billion yuan in 2024, with a year-on-year growth of 9.04%, and a net profit of 100 million yuan, reflecting a growth of 15.9% [4] - The report highlights the strong cash flow position of the company, with a net cash flow from operating activities of 498 million yuan in 2024, representing a 150.76% increase year-on-year [4] Summary by Sections Financial Performance - In Q1 2025, the company achieved a revenue of 625 million yuan, a year-on-year increase of 20.35%, and a net profit of 51 million yuan, up 13.23% [5] - The veterinary pharmaceutical segment generated a revenue of 1.234 billion yuan in 2024, with a year-on-year growth of 21.47% [6] - The company plans to increase production capacity significantly in 2025, with a target of producing 20,000 tons of gentamicin [8] Business Segments - The veterinary vaccine business generated a revenue of 344 million yuan in 2024, with a slight growth of 2.58% [9] - New products in the vaccine segment are expected to launch in 2025, potentially contributing to revenue growth [9] - The environmental business also showed steady growth, with a revenue of 143 million yuan in 2024, up 11.01% [9] Earnings Forecast - The company is projected to achieve revenues of 2.819 billion yuan, 3.321 billion yuan, and 3.935 billion yuan for the years 2025, 2026, and 2027 respectively [10] - The expected earnings per share (EPS) for 2025, 2026, and 2027 are 0.23 yuan, 0.33 yuan, and 0.37 yuan respectively [10] - The report indicates a strong growth trajectory with a forecasted net profit growth rate of 74.9% in 2025 [12]

Investment Rating - The report assigns a "Buy" rating for the company, marking the first coverage of the stock [10]. Core Views - The company is undergoing a transformation towards innovation, with significant investments in research and development expected to yield results soon [7][10]. - Despite a decline in revenue and profit due to changes in procurement and sales models, a gradual recovery in income is anticipated starting from Q2 2025 [6][10]. - The new drug AR882 is highlighted as a key product in the company's transition to an innovative pharmaceutical enterprise, with promising clinical trial results [8][10]. Summary by Sections Market Performance - The company reported a revenue of 1.45 billion yuan in 2024, a year-on-year decrease of 42.07%, and a net profit attributable to shareholders of -540 million yuan [5]. Investment Highlights - The adjustment in marketing strategies has led to significant changes in revenue and profit, with an expected recovery in sales starting Q2 2025 [6]. - R&D investment increased to approximately 324.79 million yuan in 2024, representing a 7.77% year-on-year growth and accounting for 22.40% of total revenue [7]. - The company has participated in four rounds of national drug procurement, with nine products successfully shortlisted, leading to an expected reduction in the impact of procurement on revenue [6]. Profit Forecast - Revenue projections for 2025-2027 are 1.565 billion, 1.939 billion, and 2.313 billion yuan respectively, with corresponding EPS of 0.36, 0.54, and 0.79 yuan [9][12]. - The company is expected to achieve a net profit of 163 million yuan in 2025, marking a significant turnaround from previous losses [12].

Investment Rating - The report maintains a "Recommended" investment rating for the gold, copper, aluminum, tin, and antimony industries [9]. Core Views - The report highlights a positive outlook for copper and aluminum prices due to improving downstream demand and inventory depletion [5][7]. - Gold prices are expected to maintain an upward trend supported by the ongoing interest rate cut cycle by the Federal Reserve [9]. - The tin market is anticipated to experience weak price movements due to a lack of short-term catalysts [9]. - Antimony prices are expected to remain weak in the short term, but long-term supply-demand dynamics may support prices [9]. Summary by Sections Market Performance - The non-ferrous metals sector showed a weekly increase of 2.04%, outperforming other sectors [19]. - The top-performing sub-sectors included tungsten (+4.50%), nickel (+3.79%), and aluminum (+3.78%) [19]. Copper Market - LME copper closed at $9,415 per ton, up $283 per ton (3.10%) from April 17 [5]. - SHFE copper closed at ¥77,650 per ton, up ¥1,780 per ton (2.34%) from April 17 [5]. - Domestic copper social inventory decreased significantly, indicating strong demand [6]. Aluminum Market - Domestic electrolytic aluminum prices reached ¥20,100 per ton, an increase of ¥210 per ton (1.06%) [7]. - LME aluminum inventory decreased by 12,575 tons, while domestic SHFE inventory also saw a decline [7]. - The operating rate for leading aluminum profile enterprises increased to 59.5% [8]. Tin Market - Domestic refined tin prices rose to ¥263,180 per ton, up ¥6,800 per ton (2.65%) [9]. - The market is expected to remain weak due to insufficient demand catalysts [9]. Antimony Market - Domestic antimony ingot prices fell to ¥235,500 per ton, down ¥8,000 per ton [9]. - The market activity is low, with cautious purchasing behavior from downstream buyers [9]. Recommended Stocks - The report recommends specific stocks in the gold, copper, aluminum, tin, and antimony sectors, including Zhongjin Gold, Zijin Mining, and Huaxi Youshi [10][12][13].

Investment Rating - The report maintains a "Buy" investment rating for the company [1][7] Core Insights - The company has experienced rapid growth, with total revenue reaching 477 million yuan in 2024, a year-on-year increase of 62.35%, and a net profit of 45.54 million yuan, up 198.73% [3][9] - In Q1 2025, the company reported revenue of 188 million yuan, a significant year-on-year growth of 168.82%, with net profit soaring to 40.50 million yuan, reflecting a 407.62% increase [3][9] - The company's comprehensive computing services generated revenue of 66 million yuan in 2024, with a gross margin of 82.18%, indicating strong profitability in this segment [4][9] Financial Performance - The company forecasts revenues of 2.52 billion yuan, 3.39 billion yuan, and 4.38 billion yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 1.64 yuan, 2.26 yuan, and 2.97 yuan [7][9] - The projected growth rates for revenue are 429.1% in 2025, 34.4% in 2026, and 29.2% in 2027, while net profit is expected to grow by 423.6%, 37.6%, and 31.4% over the same period [9][10] Strategic Developments - The company has introduced strategic investors to enhance its computing business, focusing on AI-related services and establishing high-performance computing centers [4][6] - The recent collective study by the Central Political Bureau on artificial intelligence underscores the strategic importance of self-reliant computing, positioning the company favorably in the market [5][6]

Investment Rating - The report maintains a "Buy" rating for several companies including Senqilin, Sinopec, Juhua, Yangnong Chemical, CNOOC, Sailun Tire, Tongkun, Zhenhua, and Guangxin [10]. Core Viewpoints - The report suggests focusing on import substitution, domestic demand, and high dividend opportunities in the chemical industry due to recent OPEC production cuts and stabilizing international oil prices [5][21]. - The report highlights that while some chemical products have seen price increases, the overall industry remains weak due to past capacity expansions and weak demand [21][32]. Summary by Sections Industry Tracking - International oil prices have shown mixed trends, with WTI at $63.02 per barrel and Brent at $66.87 per barrel as of April 25, 2025, reflecting a decline of 2.57% and 1.60% respectively [5][22]. - The domestic gasoline market has seen a slight decrease in prices, with average prices for gasoline and diesel dropping by 0.69% and 0.41% respectively [23]. Price Movements - Significant price increases were noted for products such as polymer MDI (up 7.64%) and diammonium phosphate (up 3.57%), while coal tar and sulfur saw declines of 11.11% and 9.72% respectively [20][21]. - The report indicates that the chemical industry is experiencing a mixed performance across different sectors, with some like the tire and lubricant industries performing better than expected [21][32]. Investment Opportunities - The report emphasizes the potential for investment in sectors benefiting from import substitution, such as lubricating oil additives and special coatings, as domestic products gain market share due to tariff impacts [8][21]. - It also highlights the resilience of the tire industry amid trade tensions, suggesting companies like Senqilin and Sailun Tire as potential investment opportunities [21][32]. Company Focus - Specific companies are highlighted for their strong dividend yields and market positions, including Sinopec, CNOOC, and others in the chemical sector with around 5% dividend yields [21][32].

Investment Rating - The report assigns a "Buy" rating for the company, marking the first coverage of the stock [10]. Core Views - The company is undergoing a transformation towards innovation, with significant investments in research and development expected to yield results soon [7][10]. - Despite a decline in revenue and profit due to changes in procurement and sales models, a gradual recovery in income is anticipated starting from Q2 2025 [6]. - The new drug AR882 is highlighted as a key product in the company's transition to an innovative pharmaceutical enterprise, with promising clinical trial results [8][10]. Summary by Sections Market Performance - The company reported a revenue of 1.45 billion yuan in 2024, a year-on-year decrease of 42.07%, and a net profit attributable to shareholders of -540 million yuan [5]. Investment Highlights - The adjustment in marketing strategy has led to significant changes in revenue and profit, with an expected recovery in sales starting Q2 2025 [6]. - R&D investment increased to approximately 324.79 million yuan in 2024, representing a 7.77% year-on-year growth and accounting for 22.40% of total revenue [7]. - The company has participated in four rounds of national drug procurement, with nine products successfully shortlisted, leading to an expected reduction in the impact of procurement on revenue [6]. Profit Forecast - Revenue projections for 2025-2027 are 1.565 billion, 1.939 billion, and 2.313 billion yuan respectively, with corresponding EPS of 0.36, 0.54, and 0.79 yuan [9][12]. - The company is expected to achieve a net profit of 163 million yuan in 2025, with a significant recovery in profitability anticipated in subsequent years [12].

2025 年 04 月 28 日 下游开工向好以及库存去化，铜铝价格维持较强 走势 推荐(维持) 投资要点 分析师：傅鸿浩 S1050521120004 fuhh@cfsc.com.cn 分析师：杜飞 S1050523070001 dufei2@cfsc.com.cn 行业相对表现 | 表现 | 1M | 3M | 12M | | --- | --- | --- | --- | | 有色金属(申万) | -4.8 | 2.9 | -1.6 | | 沪深 300 | -3.3 | -0.8 | 5.7 | 市场表现 -30 -20 -10 0 10 20 (%) 有色金属 沪深300 资料来源：Wind，华鑫证券研究 相关研究 1、《有色金属行业周报：关税影响 美国经济滞涨风险增大，金价支撑 仍然强劲》2025-04-21 2、《有色金属行业周报：美国通胀 持续走弱，降息预期提升支撑金 价》2025-04-14 3、《有色金属行业周报：电解铝库 存去化叠加下游需求向好，铝价偏 强看待》2025-03-31 美联储票委古尔斯比本周发言对美国经济和未来利率水平做 了点评。古尔斯比表示，短期通胀预期上升，但长期预期未 ...

业绩快速高增，算力业务打造第二成长极 买入(维持) 投资要点 分析师：宝幼琛 S1050521110002 baoyc@cfsc.com.cn 2025 年 04 月 28 日 —迈信林（688685.SH）公司动态研究报告 ▌算力综合业务初见成效，为公司的持续发展提供 有力支撑。 2024 年 9 月，公司为进一步拓展业务领域，引入战略投资者 白冰先生与徐迎辉先生。白冰先生所创立的光子算数（北 京）科技有限责任公司专注于光互联算力集群系统的构建、 交付与运营，徐迎辉先生及其团队在国产算力中心机房建 设、配套采购、客户服务层面有着较大的优势。双方一致同 意通过控股股东、实际控制人张友志先生转让 10.00%股权， 白冰先生与徐迎辉先生各受让 5.00%股权来达成合作，共同推 动上市公司战略发展。 | 基本数据 | 2 0 2 5-0 4-2 5 | | --- | --- | | 当前股价（元） | 65.15 | | 总市值（亿元） | 95 | | 总股本（百万股） | 145 | | 流通股本（百万股） | 145 | | 52 周价格范围（元） | 21.75-69.25 | | 日均成交额（百万元） ...

2025 年 04 月 28 日 业绩密集披露期，整体反馈符合预期 推荐(维持) 投资要点 | 分析师：孙山山 | S1050521110005 | | --- | --- | | sunss@cfsc.com.cn | | | 联系人：肖燕南 | S1050123060024 | | xiaoyn@cfsc.com.cn | | | 联系人：张倩 | S1050124070037 | zhangqian@cfsc.com.cn 行业相对表现 | 表现 | 1M | 3M | 12M | | --- | --- | --- | --- | | 食品饮料(申万) | -0.9 | 6.4 | -8.1 | | 沪深 300 | -3.3 | -0.8 | 5.7 | 市场表现 -10 0 10 20 (%) 食品饮料 沪深300 资料来源：Wind，华鑫证券研究 -30 相关研究 1、《食品饮料行业周报：社零数据 超预期暨一季度业绩前瞻》2025- 04-21 2、《食品饮料行业点评报告：内需 持续释放，3 月社零数据超预期》 2025-04-18 3、《食品饮料行业周报：外围环境 持续承压，期待消费需求回暖》 ...